Article Text

PDF
FRI0586 Interleukin (IL)-1 inhibition with anakinra and canakinumab in behÇet's disease related uveitis: a multicenter retrospective observational study
  1. C Fabiani1,
  2. A Vitale2,
  3. G Emmi3,
  4. G Lopalco4,
  5. L Vannozzi3,
  6. S Guerriero4,
  7. S Gentileschi2,
  8. D Bacherini3,
  9. R Franceschini2,
  10. B Frediani2,
  11. M Galeazzi2,
  12. F Iannone4,
  13. GM Tosi2,
  14. L Cantarini2
  1. 1Humanitas Research Hospital, Rozzano, Milan
  2. 2University of Siena, Siena
  3. 3University of Florence, Florence
  4. 4University of Bari, Bari, Italy

Abstract

Objectives To evaluate the role of interleukin (IL)-1 inhibitors anakinra (ANA) and canakinumab (CAN) in the treatment of Behçet disease (BD)-related uveitis

Methods multicenter retrospective observational study including 19 consecutive BD patients (31 affected eyes) receiving treatment with anti-IL-1 agents. Data were analyzed at baseline, at 3 and 12 months. Primary end-point: reduction of ocular inflammatory flares (OIF). Secondary end-points: improvement of Best Corrected Visual Acuity (BCVA); reduction of macular thickness defined by optical coherence tomography (OCT) and of vasculitis identified with fluorescein angiography (FA); evaluation of statistically significant differences between patients treated with IL-1 inhibitors as monotherapy, subjects also administered with disease modifying anti-rheumatic drugs (DMARDs) and/or corticosteroids as well as between patients administered with IL-1 inhibitors as first line biologic treatment and those previously treated with TNF-α inhibitors

Results at 12 months OIF significantly decreased from 200/100 patients/year to 48.87/100 patients/year (p<0.0001). The frequency of retinal vasculitis identified by FA significantly decreased between baseline, 3-month and 12-month follow-up visits (p<0.0001 and p=0.001, respectively). OIF rate was significantly higher in patients co-administered with DMARDs (81.8/100 patients/year) than in patients undergoing IL-1 inhibitors as monotherapy (0.0/100 patients/year) (p=0.03). No differences were identified on the basis of corticosteroid use and between patients administered with IL-1 inhibitors as first-line biologic approach or second-line. Steroid dosage was significantly decreased at 12-month visit compared to baseline (p=0.02).

Conclusions treatment with IL-1 inhibitors is effective in the management of BD-related uveitis and provides a long-term control of ocular inflammation in refractory and long-lasting cases.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.